Drug Search Results
More Filters [+]

Idarubicin

Alternative Names: idarubicin, idarubicina, idarubicine, zavedos, idamycin pfs, idamycin
Latest Update: 2024-06-14
Latest Update Note: Clinical Trial Update

Product Description

Idarubicin is a 4-demethoxy-anthracycline analogue of daunorubicin which, when administered intravenously in combination with cytarabine, has therapeutic efficacy superior to that of standard induction and salvage treatment regimens in acute myelogenous leukaemia. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/1723369/)

Mechanisms of Action: mTOR Inhibitor,TOP2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Clavis Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Idarubicin

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czech Republic, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Singapore, Spain, Sweden, Switzerland, Taiwan, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 11

Highest Development Phases

Phase 3: Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Acute Promyelocytic Leukemia|Rhabdomyosarcoma

Phase 2: Hepatocellular Carcinoma|Liver Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

AIEOP-BFM AML 2020

P3

Not yet recruiting

Acute Myeloid Leukemia

2029-12-31

IDADOX

P2

Recruiting

Hepatocellular Carcinoma|Liver Cancer

2025-12-01

TUD-APOLLO-064

P3

Active, not recruiting

Acute Myeloid Leukemia|Acute Promyelocytic Leukemia

2025-01-01

LIDA-BII

P2

Recruiting

Hepatocellular Carcinoma

2024-12-18

Recent News Events